GILD34:BVMF
Gilead Sciences Inc BDR
R$65.81
0.00%
(0.00) 1D
Oct 16, 4:56:00 PM GMT-3 · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GILD34...
Open
R$66.36
High
R$66.41
Low
R$65.81
Mkt. cap
193.67B
Avg. vol.
261.00
Volume
1.78K
52-wk high
R$67.38
52-wk low
R$51.33
Shares outstanding
1.24B
No. of employees
17K
Open
R$66.36
High
R$66.41
Low
R$65.81
Mkt. cap
193.67B
Avg. vol.
261.00
Volume
1.78K
52-wk high
R$67.38
52-wk low
R$51.33
Shares outstanding
1.24B
No. of employees
17K
News stories
From web sources and news partners
The Motley Fool
·
5 hours ago
Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?
ad-hoc-news.de
·
7 hours ago
Gilead Sciences stock trades 0.32 percent above its Xetra close
Simply Wall Street
·
1 day ago
Did Cancer Drug Partnership Just Shift Gilead's (GILD) Investment Narrative?
Investing.com Canada
·
1 day ago
Form 4 Gilead Sciences Inc: Daniel Patrick O’Day (Director, Chairman & CEO) For: 1 October
Profile
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
About Gilead Sciences Inc BDR
CEODaniel O'Day
Employees17K
FoundedJun 22, 1987
HeadquartersFoster City, California, United States
SectorBiotechnology
Websitegilead.com